73 Post-platinum treatment landscape in patients with recurrent endometrial cancer: analysis of german claims data

Introduction/Background* Recurrent or advanced endometrial cancer (EC) affects 2527 to 3245 women in Germany each year, with median survival of Methodology This study was a retrospective, noninterventional, cohort analysis that used claims data from the AOK PLUS, a statutory health insurance provider, from 01/01/2010 to 30/06/2020 for about 3.4 million individuals in Germany. Eligible patients were >18 years old, had ≥2 outpatient specialist-confirmed EC diagnoses or 1 respective inpatient diagnosis between 01/01/2011 and 30/06/2019, and 1 documented platinum-based treatment. Start of a subsequent line of treatment (LOT) after platinum was defined as the add-on of a substance or the switch to a new substance ≥3 months after regimen start. Any treatment after a gap of >3 months was also considered a new LOT. Postplatinum therapy initiation (index) was defined as the date of the first claim for an EC drug after the end of prior platinum-based therapy. Result(s)* We identified 6832 patients with EC diagnosis. Of these, 716 received a platinum-based treatment, with 201 receiving ≥1 postplatinum treatment. Median age was 71 years (35–86 years). Median (postindex) survival was 335.00 days (95% CI, 276.29–393.71 days; figure 1). Overall, 39.3% of patients received >1 LOT, 10.4% received >2 LOTs, and 2.0% received >3 LOTs after their first platinum-based treatment. The most frequent postplatinum regimen was chemotherapy with 2 agents (10.0%; table 1). Other frequently used regimens were medroxyprogesterone (8.0%), doxorubicin (7.0%), carboplatin with paclitaxel (5.5%), and paclitaxel monotherapy (4.0%). Conclusion* This claims database analysis demonstrates that treatment options are highly varied, indicating no standard of care. In this treatment landscape, survival of patients with recurrent EC remains poor. This study (217028) was sponsored by GlaxoSmithKline, Waltham, MA, USA.